Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study

BACKGROUND: 10%–15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) or POLE exonuclease domain mutations, and are characterised by high tumour mutational burden and increased lymphocytic infiltrate. Metastatic dMMR colon cancers a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Lau, David, Kalaitzaki, Eleftheria, Church, David N, Pandha, Hardev, Tomlinson, Ian, Annels, Nicola, Gerlinger, Marco, Sclafani, Francesco, Smith, Gillian, Begum, Ruwaida, Crux, Richard, Gillbanks, Angela, Wordsworth, Sarah, Chau, Ian, Starling, Naureen, Cunningham, David, Dhillon, Tony
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7046393/
https://ncbi.nlm.nih.gov/pubmed/32079623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000638
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados